UAE’s Neopharma and ASKA of Japan to build drug plant in India in $53M JV
fiercepharma | May 03, 2018
The plant is expected to open by 2020 and will produce oral solid dosage forms, oral liquids and topical preparations. The capacity of the facility is projected at 3 billion tablets a year, The Hindu reported. The plant is expected to open by 2020 and will produce oral solid dosage forms, oral liquids and topical preparations. The capacity of the facility is projected at 3 billion tablets a year, The Hindu reported. The joint venture aims to manufacture drugs for chronic therapies in cardiovascular diseases, the central nervous system and diabetes, along with other products from key therapeutic classes targeting Japan and the world market. Construction is set to begin this month at a site in J.N. Pharma City. The company said it will seek cGMP accreditation from all major global health regulatory bodies.